A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity
Authors' conclusion
An exposure-response model has been established that quantitatively describes the relationship between systemic semaglutide exposure and weight loss and predicts weight-loss trajectories for people with overweight or obesity who are receiving semaglutide doses up to 2.4 mg once weekly.
Study context
- Population
- People with overweight or obesity with or without T2D receiving semaglutide for weight management; data from one 52-week phase 2 dose-ranging trial (once-daily SC semaglutide 0.05–0.4 mg) and two 68-week phase 3 trials (once-weekly SC semaglutide 2.4 mg)
- Outcome
- Exposure-weight loss relationship
Methodological detailspopulation pharmacokinetic model, exposure-response model, external validation in three independent phase 3 trials
- Population pharmacokinetic model
- Exposure-response model
- External validation in three independent phase 3 trials
Performance
As reported in the abstract
- Based on population pharmacokinetic (PK), exposure levels over time consistently explained weight-loss trajectories across trials and dosing regimens
- Exposure-response model had high precision and limited bias for predicting body weight loss at 1 year in independent datasets
- Precision increased when data from later time points were included in the prediction
Original publication
A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity. Diabetes Obes Metab. Published 9 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →